Kumar V, Clark M J, Traynor J R, Lewis J W, Husbands S M
Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK.
Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
Bioorg Med Chem. 2014 Aug 1;22(15):4067-72. doi: 10.1016/j.bmc.2014.05.065. Epub 2014 Jun 12.
Opioid ligands have found use in a number of therapeutic areas, including for the treatment of pain and opiate addiction (using agonists) and alcohol addiction (using antagonists such as naltrexone and nalmefene). The reaction of imines, derived from the opioid ligands oxymorphone and naltrexone, with Michael acceptors leads to pyridomorphinans with structures similar to known pyrrolo- and indolomorphinans. One of the synthesized compounds, 5e, derived from oxymorphone had substantial agonist activity at delta opioid receptors but not at mu and/or kappa opioid receptors and in that sense profiled as a selective delta opioid receptor agonist. The pyridomorphinans derived from naltrexone and naloxone were all found to be non-selective potent antagonists and as such could have utility as treatments for alcohol abuse.
阿片类配体已在多个治疗领域得到应用,包括用于治疗疼痛和阿片类药物成瘾(使用激动剂)以及酒精成瘾(使用纳曲酮和纳美芬等拮抗剂)。由阿片类配体羟吗啡酮和纳曲酮衍生的亚胺与迈克尔受体反应,生成结构与已知吡咯并吗啡烷和吲哚并吗啡烷相似的吡啶吗啡烷。其中一种由羟吗啡酮衍生合成的化合物5e,在δ阿片受体上具有显著的激动剂活性,但在μ和/或κ阿片受体上没有,从这个意义上说,它被描述为一种选择性δ阿片受体激动剂。发现由纳曲酮和纳洛酮衍生的吡啶吗啡烷都是非选择性强效拮抗剂,因此可能具有治疗酒精滥用的效用。